Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding.
Journal
Blood transfusion = Trasfusione del sangue
ISSN: 2385-2070
Titre abrégé: Blood Transfus
Pays: Italy
ID NLM: 101237479
Informations de publication
Date de publication:
07 11 2023
07 11 2023
Historique:
received:
20
10
2022
accepted:
22
12
2022
medline:
6
11
2023
pubmed:
17
2
2023
entrez:
16
2
2023
Statut:
ppublish
Résumé
Emicizumab, a monoclonal bispecific antibody that mimics the function of activated factor VIII (FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with and without inhibitors. Acquired hemophilia A (AHA) is a very rare bleeding disorder caused by the development of autoantibodies that inhibit FVIII activity in plasma; males and females are equally affected. Therapeutic options for patients with AHA currently include eradication of the inhibitor with immunosuppressive treatments and management of acute bleeding with bypassing agents or recombinant porcine FVIII. More recently, several reports described the off-label use of emicizumab in patients with AHA and a phase III study is ongoing in Japan. The aims of this review are to describe the 73 reported cases, and to highlight the advantages and disadvantages of this novel approach to the prevention and treatment of bleeding in AHA.
Identifiants
pubmed: 36795341
pii: 2023.0247-22
doi: 10.2450/2023.0247-22
pmc: PMC10645354
doi:
Substances chimiques
emicizumab
7NL2E3F6K3
Factor VIII
9001-27-8
Antibodies, Monoclonal, Humanized
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
549-556Références
Haemophilia. 2023 Jan;29(1):84-89
pubmed: 36163651
J Thromb Haemost. 2012 Apr;10(4):622-31
pubmed: 22321904
Res Pract Thromb Haemost. 2019 Apr 09;3(3):420-423
pubmed: 31294330
Transfus Apher Sci. 2022 Dec;61(6):103457
pubmed: 35643753
Res Pract Thromb Haemost. 2022 Sep 09;6(6):e12785
pubmed: 36176309
Am J Hematol. 2017 Jul;92(7):695-705
pubmed: 28470674
Am J Case Rep. 2020 May 07;21:e922326
pubmed: 32376817
Eur J Case Rep Intern Med. 2021 Nov 11;8(11):002984
pubmed: 34912741
Haemophilia. 2015 Mar;21(2):162-170
pubmed: 25623166
Blood Coagul Fibrinolysis. 2022 Mar 1;33(2):138-140
pubmed: 34930862
Haemophilia. 2021 Jul;27(4):e585-e588
pubmed: 34050698
Ther Adv Hematol. 2021 Aug 28;12:20406207211038193
pubmed: 34471508
Am J Case Rep. 2019 Jul 18;20:1046-1048
pubmed: 31318850
Blood Coagul Fibrinolysis. 2018 Apr;29(3):282-287
pubmed: 29474202
Transfus Med Hemother. 2019 Apr;46(2):121-123
pubmed: 31191199
Blood. 2021 Jan 21;137(3):410-419
pubmed: 32766881
Br J Clin Pharmacol. 2023 Feb;89(2):908-913
pubmed: 36369653
Blood Transfus. 2020 Jul;18(4):312-321
pubmed: 32698943
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Hamostaseologie. 2020 Dec;40(5):561-571
pubmed: 32588417
Thromb Res. 2019 Feb;174:24-26
pubmed: 30551040